The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1408-1418

  Thornton, Michael ^a,b   Aslam, Mohammed A ^a   Tweedle, Elizabeth M ^a,b   Ang, Chin ^a   Campbell, Fiona ^b   Jackson, Richard ^a   Costello, Eithne ^a   Rooney, Paul S ^b   Vlatkovic̈, Nikolina ^a   Boyd, Mark T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

biological markers; colorectal neoplasms; GRP78; retrospective studies; tumour suppressor protein p53; unfolded protein response

Indexed keywords

FLUOROPYRIMIDINE; GLUCOSE REGULATED PROTEIN 78; PROTEIN P53; SMALL INTERFERING RNA; TUMOR MARKER;

AGED; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR INVASION; UNFOLDED PROTEIN RESPONSE;

BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; GRP78; RETROSPECTIVE STUDIES; TUMOUR SUPPRESSOR PROTEIN P53; UNFOLDED PROTEIN RESPONSE;

ADULT; AGED; APOPTOSIS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UNFOLDED PROTEIN RESPONSE;

EID: 84879924535     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28137     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50.
3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-16.
4. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-204.
5. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2011; 23: 1190-7.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
7. Petrelli N, Douglass HO, Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-26.
8. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
9. Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-9.
10. Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. J Clin Oncol 2004; 22: 3408-19.
11. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29: 3381-8.
12. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51: 503-7.
13. Lee AS,. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001; 26: 504-10.
14. Lee AS,. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-9.
15. Rutkowski DT, Kaufman RJ,. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci 2007; 32: 469-76.
16. Ron D, Walter P,. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
17. Wu J, Kaufman RJ,. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 2006; 13: 374-84.
18. Kaufman RJ,. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110: 1389-98.
19. Chiu CC, Lin CY, Lee LY, et al. Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention. Mol Cancer Ther 2008; 7: 2788-97.
20. Pootrakul L, Datar RH, Shi SR, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006; 12: 5987-93.
21. Scriven P, Coulson S, Haines R, et al. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer 2009; 101: 1692-8.
22. Mozos A, Roue G, Lopez-Guillermo A, et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol 2011; 179: 2601-10.
23. Liu M-H, Wang M-C, Gao N, et al. Expression and clinical significance of glucose regulated proteins GRP78 and GRP94 in human colon cancer. Chin J Cancer Res 2010; 22: 42-8.
24. Xing X, Lai M, Wang Y, et al. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta 2006; 364: 308-15.
25. Takahashi H, Wang JP, Zheng HC, et al. Overexpression of GRP78 and GRP94 is involved in colorectal carcinogenesis. Histol Histopathol 2011; 26: 663-71.
26. Akaike H,. A new look at the statistical model identification. IEEE Trans Automat Control 1974; 19: 716-23.
27. Maguire M, Nield PC, Devling T, et al. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res 2008; 68: 3232-42.
28. Warburton HE, Brady M, Vlatkovic N, et al. p53 regulation and function in renal cell carcinoma. Cancer Res 2005; 65: 6498-503.
29. Paton AW, Beddoe T, Thorpe CM, et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 2006; 443: 548-52.
30. Boyer J, McLean EG, Aroori S, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 2004; 10: 2158-67.
31. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9.
32. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-9.
33. Adamsen BL, Kravik KL, Clausen OP, et al. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 2007; 31: 1491-500.
34. Hsu JL, Chiang PC, Guh JH,. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 373-82.
35. Backer JM, Krivoshein AV, Hamby CV, et al. Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia 2009; 11: 1165-73.
36. O'Connell JB, Maggard MA, Ko CY,. Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5.
37. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-6.
38. Van Cutsem E, Lambrechts D, Prenen H, et al. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol 2011; 29: 1-4.
39. Lee E, Nichols P, Groshen S, et al. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 2011; 128: 726-31.
40. Hsu WM, Hsieh FJ, Jeng YM, et al. GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors. Int J Cancer 2005; 113: 920-7.
41. Zheng HC, Takahashi H, Li XH, et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 2008; 39: 1042-9.
42. Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA,. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol Biol Cell 2005; 16: 5493-501.
43. Shah MA, Schwartz GK,. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7: 2168-81.
44. Reddy RK, Mao C, Baumeister P, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003; 278: 20915-24.
45. Ni M, Zhang Y, Lee AS,. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434: 181-8.
46. Szegezdi E, Logue SE, Gorman AM, et al. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006; 7: 880-5.
47. Sun XX, Dai MS, Lu H,. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 2007; 282: 8052-9.
48. Li J, Lee B, Lee AS,. Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006; 281: 7260-70.
49. Leslie A, Carey FA, Pratt NR, et al. The colorectal adenoma-carcinoma sequence. Br J Surg 2002; 89: 845-60.
50. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29: 1261-70.